Drug Res (Stuttg) 2013; 63(06): 293-299
DOI: 10.1055/s-0033-1337927
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Disposition of the New Potent Acetylcholinesterase Inhibitor 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidiny]-1-oxopropyl]-1, 2, 5, 6-tetrahydro-4H-pyrrolo [3, 2, 1-ij] quinolin-4-one (TAK-802) in Rats, Dogs and Monkeys

M. Kakehi
1   Drug Metabolism and Pharmacokinetics Research Laboratory, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
,
Y. Tagawa
1   Drug Metabolism and Pharmacokinetics Research Laboratory, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
,
T. Kondo
1   Drug Metabolism and Pharmacokinetics Research Laboratory, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
,
S. Asahi
1   Drug Metabolism and Pharmacokinetics Research Laboratory, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 13. September 2012

accepted 16. Februar 2013

Publikationsdatum:
12. April 2013 (online)

Abstract

The pharmacokinetics of TAK-802, a potential agent of amelioration for voiding dysfunction, were investigated in rats, dogs and monkeys after a single oral administration of 14C-labeled TAK-802. The values of the bioavailability for the compound ranged from 10.2 to 19.9% and the extent of absorption of 14C were higher than the values for the bioavailability in the tested animals. TAK-802 and its related compounds distributed widely in the tissues including the target organ, the urinary bladder, in rats. TAK-802 was highly bound to the plasma proteins and the protein-binding % was independent of the spiked concentrations in all the species tested. Meanwhile, the erythrocyte distribution decreased significantly with the increase in the TAK-802 concentrations. After oral dosing, the dosed 14C was predominantly excreted into the feces of the test animals and the hepato-biliary route mainly contributed to the excretion of 14C in rats. The major components of 14C in the plasma and excreta were unidentified polar metabolites in the test animals. These results indicated that TAK-802 was extensively metabolized by first-pass metabolism during the absorption process and its related metabolites were excreted predominantly into the feces via the bile in the test animals. The concentration-dependent erythrocyte distribution was characterized as the most influential property on the pharmacokinetics of TAK-802. For the clinical safety in the development of TAK-802, the effect of the concentration-dependent erythrocyte distribution on the pharmacokinetics of TAK-802 in animals and humans should be addressed.

 
  • References

  • 1 Ameda K, Sullivan MP, Bae RJ et al. Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol 1999; 162: 142-146
  • 2 Grouts A, Gordon D, Lessing JB et al. Prevalence and characteristics of voiding difficulties in women: are subjective symptoms substantiated by objective urodynamic data?. Urology 1999; 54: 268-272
  • 3 Malone-Lee J, Wahedna I. Characterization of detrusor contractile function in relation to old age. Br J Urol 1993; 72: 973-880
  • 4 Hunter KF, Moore KN. Diabetes-associated bladder dysfunction in the older adult (CE). Geriatr Nurs 2003; 24: 138-145
  • 5 Madjar S, Appell RA. Impaired detrusor contractility: anything new?. Curr Urol Rep 2002; 3: 373-377
  • 6 Nagabukuro H, Okanishi S, Imai S et al. Effect of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rats and guinea pigs. Eur J Pharmacol 2004; 485: 299-305
  • 7 Nagabukuro H, Okanishi S, Doi T. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs. Eur J Pharmacol 2004; 494: 225-232
  • 8 Unger A, Phillips JH. Regulation of the adrenal medulla. Physiol Rev 1983; 63: 787-843
  • 9 Grdiner JE, Hellmann K, Thompson JW. The nature of the innervations of the smooth muscle, harderian gland and blood vessel of the cat’s nictitating membrane. J. Physiol 1962; 163: 436-456
  • 10 Fuse E, Tanni H, Takai K et al. Altered pharmacokinetics of a novel anticancer drug, UCn-01, caused by specific high affinity binding to alpha 1-acid glycoprotein in humans. Cancer Res 1999; 59: 1054-1060
  • 11 Sparreboom A, Chen H, Acharya MR et al. Effects of α1-Adic Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine. Clin Cancer Res 2004; 10: 6840-6846